You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Self-Replicating RNA Vaccine Against HIV-1 Delivered Using A Nanoparticle Adjuvant

    SBC: PAI LIFE SCIENCES INC            Topic: NIAID

    An effective vaccine against HIV offers the best chance to stop the global epidemic but remains elusive to dateResearch has primarily focused on subunit monomerice ggpor gpor trimeric antigensthe former approachoften adjuvanted with alumhas failed in clinical trialsNative like trimers mimic the Env spike but are still poorly immunogenic and require elaborate adjuvant screening efforts to potentiat ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Prophylactic Onchocerciasis Vaccine

    SBC: PAI LIFE SCIENCES INC            Topic: NIAID

    Humanriver blindnessis caused by a filarial parasite and is a serious neglected tropical disease contributing to blindnessskin diseaseand chronic disability in the developing worldEstimates from the Global Burden of Disease Studyindicate thatmillion cases of onchocerciasisleading tomillion cases of vision impairmentoccur worldwide every yearThe goal of this project is to develop a safe and effecti ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Rational Development of a Combination Nanoparticle Adjuvant for Influenza

    SBC: HDT BIO CORP            Topic: NIAID

    SignificanceHighly pathogenic avian H Ninfluenzawhich has killedpeople sinceis poised to cause a pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccines are insufficiently immunogenic without the addition of adjuvantsbut responses to these adjuvanted vaccines are not durable and may not be protective against newly emergent viral strainsProposed solutionWe have develop ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Person-Centered Planning ToolKit: Development of an Application to Improve Workforce Participation for Individuals with Cognitive Disabilities Through Team Collaboration and Employment Discovery

    SBC: ASSISTECH SYSTEMS LLC            Topic: na

    This project evaluates the usability and feasibility of a Person-Centered Planning Toolkit to address the need for increased opportunities for competitive integrated employment for individuals with cognitive disabilities. The Toolkit enhances implementation of person-centered planning (PCP), often limited by lack of follow-through on action items, and a lack of tools to match career preferences to ...

    SBIR Phase II 2019 Department of Health and Human ServicesAdministration for Community Living
  5. A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects

    SBC: Syntrix Biosystems, Inc.            Topic: NIDA

    Fromthe utilization of the Schedule II opioids codeineOxyContin and fentanyl declined significantlydown aboutfor all three drugsIn sharp contrastthe use of tramadola Schedule IV controlled substanceincreasedSchedule IV substances have low potential for abuse and harm relative to Schedule II substancesand the fortuitous trend to tramadol has reduced the use of the relatively unsafe Schedule II opio ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Immuno Oncology Product for Multiple Myeloma: g-NK Cellular Therapy to Optimize Monoclonal Antibody Efficacy in Treating Multiple

    SBC: Indapta Therapeutic            Topic: 102

    Project Summary Abstract Multiple myeloma is the second most common hematologic malignancy in the USwith aboutnew cases in the US each yearMost patients with MM relapse and eventually become unresponsive to treatmentAlthough multiple new therapies for MM have come on the markettheir promise is limited by concerns about toxicity and low efficacyand MM remains incurableThereforethere is an urgentdem ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Translational development of specialized NK cells for cancer immunotherapy

    SBC: Indapta Therapeutic            Topic: 102

    Project Summary Abstract The annual incidence of head and neck cancers worldwide is more thancases with arounddeaths each yearand it is estimated that inthere will benew cases of non Hodgkin lymphoma with an estimateddeaths this yearIn this proposalwe describe a strategy to use a novel subset of natural killer cellsg NK cellsallogeneically for cancer therapyWe hypothesize that expansion and adopti ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Production and Validation of Sj-p80 as a Veterinary Schistosomiasis Vaccine

    SBC: PAI LIFE SCIENCES INC            Topic: NIAID

    Project Summary More thanbillion people are at risk worldwide for developing schistosomiasis caused by one of five species of SchistosomaTwo species that cause the most human diseaseSchistosoma japonicum and Schistosoma mansoniinfect the intestine and liver by similar processesbut differ in their geographically distributionNeither are thought to be containedand both have increased their global foo ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients

    SBC: LUMITHERA INC            Topic: NEI

    As the population continues to age, degenerative ocular diseases become increasingly common and create a tremendous burden on the health care system. Age-related macular degeneration (AMD) represents a significant problem with 10-11 million patients at risk to progress to severe vision loss in the U.S. alone and the prevalence of AMD is expected to double by 2020. The dry and wet forms of the dise ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Rapid Array Diagnosis of Congenital Heart Defects (RAD4CHD) Using Allele Diagnostics Rapid Array Chromosomal Microarray Strategy

    SBC: ALLELE DIAGNOSTICS INC            Topic: NHLBI

    Allele Diagnostics Phase I SBIRProject SummaryAllele Diagnostics is a CLIA certifiedCAP accredited clinical genetics testing laboratory that was formed inOur laboratory focuses on both diagnostic testing and product developmentWe have developed a novel custom designedwhole genome chromosomal microarrayCMAwhich provides results in as little asdays in both prenatal and postnatal settingsThe successf ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government